© 2001 European Society of Cardiology
Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction
a CNR Institute of Clinical Physiology via Savi no. 8, 56126 Pisa, Italy
b Department of Science of Man and Environment, University of Pisa Pisa, Italy
* Corresponding author. Tel.: +39-50-583-277; fax: +39-50-553-461. E-mail address: balzan{at}ifc.pi.cnr.it (S. Balzan).
 |
Abstract |
|---|
Background: Much evidence has been accumulated that human plasma contains digitalis-like factor(s) with Na/K ATPase inhibitor properties. Increased concentrations of ouabain-like factor (OLF) have been reported in patients with moderate to severe hypertension and in patients with overt congestive heart failure due to dilated cardiomyopathy.
Aim: The presence of circulating OLF has not been investigated in borderline to mild hypertension or in the early stage of dilated cardiomyopathy.
Methods and Results: The study population consisted of 18 normal volunteers, 24 patients with borderline to mild hypertension, 47 patients with asymptomatic left ventricular dysfunction (ALVD) due to dilated cardiomyopathy and 26 patients with cardiac arrhythmias but normal left ventricular function. OLF values (pM ouabain equivalent) were assayed in extracted plasma, using a radioimmunoassay for ouabain. OLF was, respectively, 29.4 ± 20.6 pM in normal controls, 39.1 ± 23.8 pM in hypertensives, 35 ± 18 pM in patients with cardiac arrhythmias, 52.3 ± 25.8 pM in ALVD patients not treated with digoxin and 64.6 ± 29.6 pM in ALVD patients treated with digoxin. Patients with ALVD, both treated and not treated with digoxin, had OLF significantly higher (P < 0.05) than all the other groups. In patients with ALVD no correlation between OLF and left ventricular ejection fraction was observed. In the hypertensive group no correlation between OLF and both diastolic and systolic pressure was found.
Conclusion: Increased concentrations of OLF were observed in patients with left ventricular dysfunction due to dilated cardiomyopathy, before the occurrence of overt heart failure, suggesting that OLF may be an early marker of the disease.
Key Words: Ouabain • Dilated cardiomyopathy • Hypertension • Cardiac arrhythmias
Received May 9, 2000; Revised August 2, 2000; Accepted October 12, 2000
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. N. Wansapura, V. Lasko, Z. Xie, O. V. Fedorova, A. Y. Bagrov, J. B Lingrel, and J. N. Lorenz Marinobufagenin enhances cardiac contractility in mice with ouabain-sensitive {alpha}1 Na+-K+-ATPase Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1833 - H1839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Y. Bagrov, J. I. Shapiro, and O. V. Fedorova Endogenous Cardiotonic Steroids: Physiology, Pharmacology, and Novel Therapeutic Targets Pharmacol. Rev., March 1, 2009; 61(1): 9 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Schoner and G. Scheiner-Bobis Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth Am J Physiol Cell Physiol, August 1, 2007; 293(2): C509 - C536. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ferrandi, I. Molinari, P. Barassi, E. Minotti, G. Bianchi, and P. Ferrari Organ Hypertrophic Signaling within Caveolae Membrane Subdomains Triggered by Ouabain and Antagonized by PST 2238 J. Biol. Chem., August 6, 2004; 279(32): 33306 - 33314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Jortani, S. D. Prabhu, and R. Valdes Jr Strategies for Developing Biomarkers of Heart Failure Clin. Chem., February 1, 2004; 50(2): 265 - 278. [Abstract] [Full Text] [PDF]
|
|